The aim of this study is to report outcomes of patients with Hodgkin Disease (HD) after high dose therapy and autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) in a single center in Colombia. One hundred four patients with relapsed or refractory HD were treated with auto-HSCT between 1994 and 2008. Clinical status previous to transplantation, and events as relapse or death were analyzed to establish 5 year Overall Survival (OS) and Event Free Survival (EFS). One hundred four patients have had 105 procedures (one patient with 2 auto-SCT). Thirty-five female and 69 male, 79 adults and 25 less than 16 years, with average age of 27.4 years (range 5 to 66 yrs). Forty-one patients (39,4%) with refractory disease, 21 with early relapse (20%) and 42 with late relapse (40,4%). Clinical stage at diagnosis: I and IIA 24 patients (23%), IIB 28 patients (26.9%), IIIA 7 patients (6.7%), III B 21 patients (20%), stage IV 21 patients (20%) and (3 patients unknown). The source of cells was peripheral blood in 95 transplants (91.4%), bone marrow in 6 (5.7%) and combined in 2 procedures (1.9%) combined, (2 patients unknown). The conditioning chemotherapy was BEAM in 56 transplants (53.3%), cyclophosphamyde-etoposide-melphalan in 26 (24.7%) and other protocols in 23 (21.9%) transplants. At the time of transplantation, 61 patients (58%) were in complete remission, 36 (34%) in partial remission and 5 (4.7%) with active disease. Twenty nine patients had relapse, of them 11 are dead. Seven patients had non relapse mortality: 5 with infectious complications, 1 with colecistitis and 1 with graft failure. Two patients died for complications of a second neoplasm. The mortality in the first 100-days was 3% (3 patients with infectious complications). With a median of 971 days of follow-up (range 12 to 5587 days), 59 (56.7%) patients are in complete remission, 17 (16.3%) are alive after relapse, 21 (20.1%) have died and 7 (6.7%) were lost for follow-up. Near 50% of patients with refractory or relapsed HD can be successfully treated with high dose chemotherapy and autologous stem cell transplantation.